Antibiotic Treatment for Klebsiella pneumoniae UTI in CKD Patients

First-line Treatment Options

The Infectious Diseases Society of America recommends aminoglycosides as first-line therapy for urinary tract infections caused by Klebsiella pneumoniae, especially in CKD patients, due to their excellent urinary concentrations and high clinical cure rates 1, 2
A single-dose aminoglycoside regimen may be sufficient for simple cystitis, as aminoglycosides achieve urinary concentrations 25-100 times higher than plasma levels 3

The National Kidney Foundation suggests that therapeutic drug monitoring is strongly recommended when using aminoglycosides in CKD patients to optimize dosing, improve efficacy, and reduce nephrotoxicity 4, 5
The American College of Nephrology recommends avoiding nephrotoxic antibiotics such as traditional aminoglycoside regimens, tetracyclines, and nitrofurantoin in CKD patients 6, 7

The European Society of Clinical Microbiology and Infectious Diseases recommends ceftazidime-avibactam or meropenem-vaborbactam for complicated UTIs caused by carbapenem-resistant Klebsiella pneumoniae (CRKP) 3, 8
The Infectious Diseases Society of America suggests that imipenem-cilastatin-relebactam may also be considered for CRKP infections 3, 8

The American College of Clinical Pharmacy recommends monitoring renal function regularly during treatment 6, 7
The Infectious Diseases Society of America suggests performing therapeutic drug monitoring for aminoglycosides, polymyxins, and carbapenems 4, 5
Treatment duration for uncomplicated UTIs is 7-10 days, and for complicated UTIs is 10-14 days, depending on clinical response 3

The Infectious Diseases Society of America recommends ceftazidime-avibactam or meropenem-vaborbactam as first-line therapy for carbapenem-resistant Klebsiella pneumoniae UTIs 9
For ESBL-producing Klebsiella pneumoniae, fosfomycin is a recommended oral option for uncomplicated UTI, with a single dose of 3 g 9

The American Society of Health-System Pharmacists suggests mandatory therapeutic drug monitoring for aminoglycosides, polymyxins, and carbapenems in all patients, especially those with renal dysfunction 10
It is recommended to avoid nephrotoxic combinations, such as combining aminoglycosides with polymyxins or other nephrotoxic agents, and to adjust doses based on creatinine clearance for all renally-eliminated antibiotics 11

The European Society of Clinical Microbiology and Infectious Diseases recommends a minimum treatment duration of 10-14 days for CRKP infections, guided by clinical response 9
The World Health Organization suggests verifying carbapenem MIC before using polymyxin-carbapenem combinations, as they are only effective if meropenem MIC ≤8 mg/L for CRE 11
The Society of Critical Care Medicine recommends avoiding delay in switching to targeted therapy once susceptibility results are available, as carbapenem overuse drives resistance 12

For patients with carbapenem-susceptible K. pneumoniae, the preferred option is Ceftazidime-avibactam 2.5g IV every 8 hours with renal dose adjustment, with a duration of 5-7 days for uncomplicated UTI, as recommended by the Journal of Microbiology, Immunology and Infection 13
Ceftazidime-avibactam 2.5g IV every 8 hours (renally adjusted) is also recommended as first-line therapy for carbapenem-resistant K. pneumoniae, with clinical success rates of 60-80%, according to the Journal of Microbiology, Immunology and Infection 13
Meropenem-vaborbactam 4g IV every 8 hours (renally adjusted) and Imipenem-cilastatin-relebactam 1.25g IV every 6 hours (renally adjusted) are second-line options for carbapenem-resistant K. pneumoniae, as recommended by the Journal of Microbiology, Immunology and Infection 13
Gentamicin 5-7 mg/kg IV once daily OR Amikacin 15 mg/kg IV once daily can be considered for patients with stable CKD, with mandatory peak and trough monitoring, and a duration of 5-7 days maximum, according to the Journal of Microbiology, Immunology and Infection 13
Tigecycline as monotherapy is not recommended due to its poor performance in bloodstream infections and inferiority to aminoglycosides for UTI, as reported by Clinical Microbiology and Infection 14